NNNN - Anbio Biotechnology Class A Ordinary Shares

NNNN - Anbio Biotechnology Class A Ordinary Shares

https://www.anbio.com

Momentum: Bearish

Recent News

Powered by Alpha Vantage

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System - Anbio Biotechnology ( NASDAQ:NNNN )

Benzinga • 1 month ago • score: 0.27

FRANKFURT, Germany, Aug. 08, 2025 ( GLOBE NEWSWIRE ) -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has announced the launch of its Chikungunya IgM/IgG Rapid Test, offering clinicians and public health authorities a fast, accessible diagnostic tool at the point of ...

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

GlobeNewswire • 1 month ago • score: 0.27

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics ...

Anbio Biotechnology to Showcase Global Diagnostic Innovations at Three Major May Exhibitions - Anbio Biotechnology ( NASDAQ:NNNN )

Benzinga • 4 months ago • score: 0.41

BRUSSELS, May 15, 2025 ( GLOBE NEWSWIRE ) -- Anbio Biotechnology, a global leader in in-vitro diagnostic ( IVD ) technologies, is pleased to announce its participation in three major international exhibitions this May: EuroMedLab 2025 in Brussels, AVA Conference 2025 in Sydney, and the 47th ...

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, Africa, and internationally. The company is headquartered in Frankfurt am Main, Germany.

52W High

$55.65

52W Low

$5.18

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

N/A

Valuation

Rich

As of 2024-12-31 (Overview)

Trailing P/E (<15 better)

858.33

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

864.23

EV/Revenue (<3 favorable)

250.54

P/S (TTM) (<3 favorable)

276.16

P/B (<3 favorable)

119.97

Ownership

Retail‑heavy

Source: Overview

Insiders (1–5% typical)

4.79%

Institutions (25–75% balanced)

4.94%

Shares Outstanding

43,891,200

Float

39,691,300

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2024-12-31 (Overview)

Revenue (TTM)

8,185,100

Gross Profit (TTM)

5,885,400

EPS (TTM)

0.06

Profit Margin (>10% good)

0.29%

Operating Margin (TTM) (higher better)

-0.69%

ROE (TTM) (>15% strong)

0.15%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.36

Momentum

Bearish momentum

Value

-0.4581

Previous

-0.1597

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025